Clinical Trial

Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES PET/CT brain scan will be completed before this standard of care radiation treatment. Patients will be followed prospectively with clinical and MRI assessments per standard-of-care for a total of 12 months. Study Population: Patients with ER-positive breast cancer with biopsy proven or suspected new or recurrent brain metastases (based on standard of care MRI) planned for radiation treatment of brain lesions.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-10-02; most recent amendment 2025-11-18.
Status change: Not Yet Recruiting → Recruiting 2023-12-11
Trial Details
NCT Number NCT06072807
Lead Sponsor Weill Medical College of Cornell University
Collaborators: GE Healthcare
Conditions Breast Cancer, Brain Metastases
Enrollment 20 participants
Start Date 2023-12-27
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-24